SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathwayXingchen Peng, Youxue Zhao|Cell Death and Disease|2014Cited by 27
Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trialZhigong Wei, Xingchen Peng|Nature Communications|2025Cited by 1